Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis

NCT05403541 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Generalized Myasthenia Gravis

Interventions

DRUG: Batoclimab 680 mg SC weekly
DRUG: Batoclimab 340 mg SC weekly
DRUG: Matching Placebo SC
DRUG: Batoclimab 340 mg SC bi-weekly

Sponsor

Immunovant Sciences GmbH